Details

Autor(en) / Beteiligte

• Mateo, Joaquin
• Cheng, Heather H.
• Beltran, Himisha
• Dolling, David
• Xu, Wen
• Pritchard, Colin C.
• Mossop, Helen
• Rescigno, Pasquale
• Perez-Lopez, Raquel
• Sailer, Verena
• Kolinsky, Michael
• Balasopoulou, Ada
• Bertan, Claudia
• Nanus, David M.
• Tagawa, Scott T.
• Thorne, Heather
• Montgomery, Bruce
• Carreira, Suzanne
• Sandhu, Shahneen
• Rubin, Mark A.
• Nelson, Peter S.
• de Bono, Johann S.

Titel

Clinical Outcome of Prostate Cancer Patients with Germline DNA Repair Mutations: Retrospective Analysis from an International Study

Ist Teil von

• European urology, 2018-05, Vol.73 (5), p.687-693

Ort / Verlag

Switzerland: Elsevier B.V

Erscheinungsjahr

2018

Quelle

MEDLINE

Beschreibungen/Notizen

• Germline DNA damage repair gene mutation (gDDRm) is found in >10% of metastatic prostate cancer (mPC). Their prognostic and predictive impact relating to standard therapies is unclear. To determine whether gDDRm status impacts benefit from established therapies in mPC. This is a retrospective, international, observational study. Medical records were reviewed for 390 mPC patients with known gDDRm status. All 372 patients from Royal Marsden (UK), Weill-Cornell (NY), and University of Washington (WA) were previously included in a prevalence study (Pritchard, NEJM 2016); the remaining 18 were gBRCA1/2m carriers, from the kConFab consortium, Australia. Response rate (RR), progression-free survival (PFS), and overall survival (OS) data were collected. To account for potential differences between cohorts, a mixed-effect model (Weibull distribution) with random intercept per cohort was used. The gDDRm status was known for all 390 patients (60 carriers of gDDRm [gDDRm+], including 37 gBRCA2m, and 330 cases not found to carry gDDRm [gDDRm–]); 74% and 69% were treated with docetaxel and abiraterone/enzalutamide, respectively, and 36% received PARP inhibitors (PARPi) and/or platinum. Median OS from castration resistance was similar among groups (3.2 vs 3.0 yr, p=0.73). Median docetaxel PFS for gDDRm+ (6.8 mo) was not significantly different from that for gDDRm– (5.1 mo), and RRs were similar (gDDRm+=61%; gDDRm–=54%). There were no significant differences in median PFS and RR on first-line abiraterone/enzalutamide (gDDRm+=8.3 mo, gDDRm–=8.3 mo; gDDRm+=46%, gDDRm–=56%). Interaction test for PARPi/platinum and gDDRm+ resulted in an OS adjusted hazard ratio of 0.59 (95% confidence interval 0.28–1.25; p=0.17). Results are limited by the retrospective nature of the analysis. mPC patients with gDDRm appeared to benefit from standard therapies similarly to the overall population; prospective studies are ongoing to investigate the impact of PARPi/platinum. Patients with inherited DNA repair mutations benefit from standard therapies similarly to other metastatic prostate cancer patients. Metastatic prostate cancer patients carrying germline mutations in DNA damage repair genes derive similar benefit from standard of care taxanes and androgen receptor signalling inhibitors to the overall population. Moreover, this exploratory analysis supports further investigation of the impact of PARP inhibitors and platinum chemotherapy in this subset of patients.